Amniotic Cell Reprogramming for Stable Endothelial Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating human endothelial cells from non-vascular sources, such as amniotic cells, face challenges in achieving stable and clinically relevant scales while maintaining angiogenic signature, due to limited expansion potential and phenotypic instability.
Innovation Solution
Enforced expression of ETS-TFs (ETV2, FLI1, and ERG) in conjunction with suppression of the TGFβ signaling pathway in amniotic cells to reprogram them into stable vascular endothelial cells (rAC-VECs) that can form perfused vasculature and engraft into liver sinusoidal endothelium.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If human adult-derived ECs are cultivated and expanded, then the expansion potential is limited, but the phenotypic stability is maintained
Solution Approach 1:
The patent changes the source cell parameter from adult-derived ECs to amniotic fluid-derived cells, which inherently possess higher proliferative capacity while maintaining phenotypic stability. This parameter change in cell origin resolves the contradiction by providing a cell source that naturally exhibits both high expansion potential and maintained phenotypic characteristics during cultivation.
2Productivity
If ECs are derived from hESCs and iPSCs, then the proliferative capacity is enhanced, but the phenotypic stability deteriorates with serial passaging
Solution Approach 1:
The patent changes the cell source parameter from hESCs/iPSCs to amniotic fluid-derived cells, which provide robust proliferative capacity similar to stem cells but maintain phenotypic stability without drift to non-vascular lineages during serial passaging. This parameter change resolves the contradiction by selecting a cell source that inherently balances high productivity with phenotypic reliability.
3Productivity
If EPCs and ECFCs are cultured in pooled platelet-rich plasma, then the proliferative potential is significant, but the vascular stability is insufficient for clinical scale propagation
Solution Approach 1:
The patent changes the cell source parameter from EPCs/ECFCs to amniotic fluid-derived cells, which inherently possess both significant proliferative potential and the vascular stability required for clinical scale propagation. This parameter change resolves the contradiction by selecting a cell source that naturally exhibits both high productivity and phenotypic reliability without requiring specialized culture conditions.
Data Source
AI summary
This disclosure is directed to methods for reproducibly generating substantial amounts of endothelial cells from amniotic cells. The endothelial cells generated in accordance with the present methodology, as well as therapeutic methods utilizing these cells, are also disclosed.